Molecule Partner Indication China Ph3 / Pivotal Clinical Status
Planning Enrollment Global APAC
OncologySacituzumab
govitecan
(Trodelvy)
mTNBC (2L)
BLA approved in USBLA accepted in China with priority review; NDA submitted in Singapore
HR+, HER2- (3L)
Phase 3
mUC (2/3L)
BLA approved in USSeek BLA approval based on US approval
mTNBC (1L)
Phase 2
NSCLC (2L)
Phase 3-
Asia basket trial
Phase 2-
FGF401HCC
Phase 1/2
ImmunologyEtrasimodUlcerative colitis
Phase 3South Korea and Taiwan included in regional trial
Other autoimmune diseases
(CD, AD)
Phase 2/3(1)
Cardio-Renal
Disease
NefeconlgA nephropathy
Phase 3NDA filed in US; Seek NDA approval based on US approval
RalinepagPAH
Phase 3
XNW1011Renal disease
Phase 2
Infectious
Disease
PTX-COVID19-B and other COVID-19 VaccinesCOVID-19
Phase 2/3
Eravacycline
(Xerava)
cIAI
NDA approved in US, EU and SingaporeNDA approved in Singapore; NDA filed and accepted in China
CABP
Phase 3-
Taniborbactam
(VNRX-5133)
cUTI
Phase 3
SPR206Gram negative infections
Phase 1

Abbreviations: mTNBC = metastatic triple-negative breast cancer; HR+/HER2- = hormone receptor-positive/human epidermal growth factor receptor 2-negative; mUC = metastatic urothelial cancer; HCC = hepatocellular carcinoma; CD = Crohn’s disease; AD = atopic dermatitis; IgA = immunoglobulin A; PAH = pulmonary arterial hypertension; cIAI = complicated intra-abdominal infections; cUTI = complicated urinary tract infections; IND = investigational new drug; BLA = biologics license application; NDA = new drug application; 1L = first-line of treatment; 2L = second- line of treatment; 3L = third-line of treatment.
Notes: 
(1) Arena is conducting a Phase 2/3 program for CD and a Phase 2b program for AD.
 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers